


Revised Structures for the Kinamycin Antibiotics: 5-Diazobenzo[b]fluorenes Rather Than Benzo[b]carbazole Cyanamides

Steven J. Gould,* Nuria Tamayo, Chris R. Melville, and Martha C. Cone

Department of Chemistry
Oregon State University
Corvallis, Oregon 97331-4003

Received October 12, 1993

The kinamycin antibiotics, first reported in 1970,¹ were isolated from *Streptomyces murayamaensis*, and they were characterized as benzo[b]carbazoloquinone cyanamides (e.g., 1 for kinamycin D, KD) on the basis of chemical, spectroscopic, and X-ray crystallographic data.^{2–5} In 1989⁶ and 1992⁷ the first additional organisms to produce kinamycins were reported. We have studied the biosynthesis of the kinamycins extensively and have established that they are polyketides derived from the benz[a]anthraquinone dehydrorabelomycin, 2.^{8–11} A number of intermediates between 2 and 1 have been isolated and characterized, including a purple metabolite that we had characterized as 3, and had named prekinamycin.^{12,13} Results from synthetic studies from other laboratories have led us to reexamine these structures. We now report a revised structure for the skeleton of the kinamycins.



¹H NMR spectroscopic data had been used to identify the substitution patterns of the naphthoquinone system and the highly oxygenated D-ring of the kinamycins.⁵ The unusual cyanamide moiety had been assigned from the infrared absorbance (ca. 2150 cm⁻¹) and from detection of ammonia upon subjecting the kinamycins to hydrolytic conditions.⁵ An X-ray diffraction study of a crystal of kinamycin C *p*-bromobenzoate, 4, appeared to confirm these features.⁴ When we initiated our biosynthetic studies, we were able to observe and assign ¹³C NMR resonances

for all carbons except the cyanamide, which was expected to occur at ca. δ 110–120.^{8,14} This resonance was subsequently found at δ 78 by generating a sample of kinamycin D from a fermentation using (¹⁵NH₄)₂SO₄ as the sole nitrogen source.¹¹ The unusual chemical shift could not be readily explained, but was attributed to possible electronic effects of the indoloquinone.

Numerous researchers have been attempting to synthesize members of the kinamycin family.^{15–20} A set of *N*-cyanoindoles has been prepared, and the IR absorbances (2237–2245 cm⁻¹) and ¹³C NMR resonances (δ 105–108) agreed poorly with data from the kinamycins.¹⁷ Echavarren's group has recently reported²¹ the synthesis of 3, and spectroscopic data did not match the natural product. Advanced intermediates in this synthesis already possessing a cyanamide moiety exhibited ¹³C NMR spectra containing a resonance at approximately δ 112,²² rather than one in the region of δ 78. Furthermore, these compounds, as well as synthetic 3, exhibited IR absorbances consistently in the region of 2250 cm⁻¹.^{23,24} Reconsideration of the cyanamide moiety was in order, and since the structural solution for 4 had given R = 8.9%,⁴ it was possible that the original crystallographic data set may not have distinguished R₂NC≡N from R₂CN≡N or R₂NN≡C (charges not shown). The diazo alternative was clearly possible: ¹³C NMR resonances of a number of diazo compounds have been observed in the δ 60–80 region, including 9-diazo-fluorene at δ 63.2.²⁵

Although only small quantities of prekinamycin had been available from fermentations of *S. murayamaensis*, substantial quantities recently became available from a mutant blocked in the kinamycin pathway that was found to overproduce prekinamycin (ca. 100 mg/L).²⁶ We tried unsuccessfully to obtain a crystal of prekinamycin, or of a simple derivative, suitable for X-ray diffraction; however, treatment of prekinamycin with Rh₂(OAc)₄²⁷ in methanol yielded a single main product that proved to be the fluorene 5.²⁸ A key problem in the data set for prekinamycin had been the lack of any observable long-range ¹³C–¹H couplings directly linking the naphthoquinone A/B-rings with the phenolic D-ring. Now, however, a ³J_{CH} coupling was observed between the new olefinic hydrogen (δ 7.25) and the semiquinone phenolic carbon (δ 150.2), and an NOE was observed between this hydrogen and the hydrogen para to the D-ring phenol (δ 6.92). All other predictable ³J_{CH}'s were also observed, including one between H-10 and the semiquinone carbonyl (δ 198.0). Concurrently, the (+)-α-methylbutyrate of kinamycin D was prepared using the acid anhydride and ZnCl₂ catalysis²⁸ and crystallized by diffusion of water into a DMF solution. A single crystal of this derivative (orthorhombic space group P2₁2₁2₁)

(14) Sato, Y.; Geckle, M.; Gould, S. J. *Tetrahedron Lett.* **1985**, 26, 4019–4022.

(15) Liebeskind, L. S.; Iyee, S.; Jewell, J. C. F. *J. Org. Chem.* **1986**, 51, 3065–3067.

(16) Weeratunga, G.; Prasad, G. K. B.; Dilley, J.; Taylor, N. J. *Dmitrienko, G. I. Tetrahedron Lett.* **1990**, 31, 5713–5716.

(17) Dmitrienko, G. I.; Nielsen, K. E.; Steingart, C.; Ming, N. S.; Willson, J. M.; Weeratunga, G. *Tetrahedron Lett.* **1990**, 31, 3681–3684.

(18) Kobayashi, K.; Takeuchi, H.; Seko, S.; Sugimoto, H. *Helv. Chim. Acta* **1991**, 74, 1091–1094.

(19) O'Sullivan, P. J.; Moreno, R.; Murphy, W. S. *Tetrahedron Lett.* **1992**, 33, 535–538.

(20) Saá, J. M.; Marti, C.; Garcia-Raso, A. *J. Org. Chem.* **1992**, 57, 589–594.

(21) Echavarren, A. M.; Tamayo, N.; Parades, M. C. *Tetrahedron Lett.* **1993**, 34, 4713–4716.

(22) Echavarren, A. M. Personal communication.

(23) Jonczyk, A.; Ochal, Z.; Makosza, M. *Synthesis* **1978**, 882–883.

(24) Liu-vien, D.; Colthup, N. B.; Fateley, W. G.; Grasselli, J. G. *The Handbook of Infrared and Raman Characteristic Frequencies of Organic Molecules*; Academic Press: London, 1991; p 111.

(25) Duthaler, R. O.; Förster, H. G.; Roberts, J. D. *J. Am. Chem. Soc.* **1978**, 100, 4974–4979.

(26) Cone, M. C.; Gould, S. J. Unpublished results.

(27) Collman, J. P.; Hegedus, L. S.; Norton, J. R.; Finke, R. G. *Principles and Applications of Organotransition Metal Chemistry*; University Books: Mill Valley, CA, 1987; p 800.

(28) Complete characterization of new compounds has been obtained.

- (1) Ito, S.; Matsuya, T.; Omura, S.; Otani, M.; Nakagawa, A.; Takeshima, H.; Iwai, Y.; Ohtani, M.; Hata, T. *J. Antibiot.* **1970**, 23, 315–316.
(2) Hata, T.; Omura, S.; Iwai, Y.; Nakagawa, A.; Otani, M. *J. Antibiot.* **1971**, 24, 353–359.
(3) Omura, S.; Nakagawa, A.; Yamada, H.; Hata, T.; Furusaki, A.; Watanabe, T. *Chem. Pharm. Bull.* **1971**, 19, 2428–2430.
(4) Furusaki, A.; Matsui, M.; Watanabe, T.; Omura, S.; Nakagawa, A.; Hata, T. *Is. J. Chem.* **1972**, 10, 173–187.
(5) Omura, S.; Nakagawa, A.; Yamada, H.; Hata, T.; Furusaki, A.; Watanabe, T. *Chem. Pharm. Bull.* **1973**, 21, 931–940.
(6) Isshiki, K.; Sawa, T.; Naganawa, H.; Matsuda, N.; Hattori, S.; Hamada, M.; Takeuchi, T. *J. Antibiot.* **1989**, 42, 467–469.
(7) Smitka, T. A.; Bonjouklian, R.; Perun, J. T., Jr.; Hunt, A. H.; Boeck, L. D.; Yao, R. C. *J. Antibiot.* **1992**, 45, 433–443.
(8) Sato, Y.; Gould, S. J. *Tetrahedron Lett.* **1985**, 26, 4023–4026.
(9) Sato, Y.; Gould, S. J. *J. Am. Chem. Soc.* **1986**, 108, 4625–4631.
(10) Seaton, P. J.; Gould, S. J. *J. Am. Chem. Soc.* **1987**, 109, 5282–5284.
(11) Seaton, P. J.; Gould, S. J. *J. Am. Chem. Soc.* **1988**, 110, 5912–5914.
(12) Cone, M. C.; Seaton, P. J.; Halley, K. A.; Gould, S. J. *J. Antibiot.* **1989**, 42, 179–188.
(13) Seaton, P. J.; Gould, S. J. *J. Antibiot.* **1989**, 42, 189–197.






Figure 1. ORTEP drawing from the single-crystal X-ray structure determination of **6**. Hydrogens have been omitted for clarity.

was analyzed by X-ray diffraction, and the direct methods program SHELXS (TEXSAN²⁹ crystallographic software package) was used to determine the positions of all non-hydrogen atoms, based on 2577 unique observations. Final cycle anisotropic refinement with a DIFABS absorption correction³⁰ gave $R = 5.18\%$ and $R_w = 5.63\%$ for the diazo structure **6** (see Figure 1 for ORTEP plot), which was significantly better than the values obtained for the cyanamide (5.69 and 6.35%, respectively) or the isonitrile (5.73 and 6.41%, respectively). Furthermore, when the data set was solved for a cyanamide structure, the calculated temperature factor for the putative cyanamide carbon was anomalously low compared to those of the remaining non-hydrogen atoms, indicating that more electron density exists at this position than would be accounted for by carbon.



From these results, it is clear that prekinamycin is the diazo compound **7**, of which all the kinamycins are derivatives (e.g., KD = **8**). Naturally-occurring diazo compounds have been very rare.^{31–33} The benzo[*b*]fluorene skeleton has been unknown among natural products, but we recently reported the structure

of kinafluorenone, **9**, from another *S. murayamaensis* blocked mutant.³⁴ In addition, examination of an HPLC/photodiode array data base of extracts of our blocked mutants has now revealed the presence of **5**.³⁵ While we had suggested formation of the benzo[*b*]fluorene skeleton to be a shunt pathway from kinamycin biosynthesis, it now must be considered an essential feature. During the past year, two other *Streptomyces* species have been reported to produce benzo[*b*]fluorene derivatives, including two with an amino group at C-5 (e.g., **10**).^{36–38} Either 12-deoxy-**10**, 7-*O*-demethyl-**9**, or **5** may prove to be intermediates in kinamycin biosynthesis. This is currently under investigation.



Acknowledgment. This research was supported by U.S. Public Health Service Grant GM 31715 to S.J.G. The N. L. Tarter Charitable Trust to Oregon State University provided partial support for C.R.M., and the Ministerio de Educacion y Ciencia (Spain) is thanked for a postdoctoral fellowship for N.T. Professor S. Omura of Kitasato University and Professor U. Hornemann of the University of Wisconsin are thanked for cultures of *S. murayamaensis*. Professor A. Echavarren of Universidad Antónoma de Madrid is thanked for helpful discussions. The Bruker AC 300 NMR spectrometer was purchased in part through grants from the Public Health Service Division of Research Resources (RR04039) and the National Science Foundation (CHE-8712343) to Oregon State University.

Supplementary Material Available: Tables I–V containing relevant details of the X-ray crystallographic studies, atomic parameters, bond distances, bond angles, and anisotropic thermal parameters (8 pages); Table VI containing structure factor amplitudes (18 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

(34) Cone, M. C.; Melville, C. R.; Gore, M. P.; Gould, S. J. *J. Org. Chem.* **1993**, *58*, 1058–1061.

(35) Tamayo, N.; Gould, S. J. Unpublished results.

(36) Shin-ya, K.; Furihata, K.; Teshima, Y.; Hayakawa, Y.; Seto, H. *Tetrahedron Lett.* **1992**, *33*, 7025–7028.

(37) Aoyama, T.; Zhao, W.; Kojima, F.; Muraoka, Y.; Naganawa, H.; Takeuchi, T.; Aoyagi, T. *J. Antibiot.* **1993**, *46*, 1471–1474.

(38) We suggest that the atoms of all derivatives of benzo[*b*]fluorene metabolites be numbered as shown in **5**, which is consistent with the standard numbering of the benz[*a*]anthraquinone biosynthetic precursors¹⁰ and with *Chemical Abstracts*.

(29) Molecular Structures Corporation. TEXSAN. MSC, 3200A Research Forest Drive, The Woodlands, TX 77381, 1988.

(30) Walker, N.; Stuart, D.; *Acta Crystallogr.* **1983**, *A39*, 158–166.

(31) Fusari, S. A.; Frohardt, R. P.; Ryder, A.; Haskell, T. H.; Johannessen, D. W.; Elder, C. C.; Bartz, Q. R. *J. Am. Chem. Soc.* **1954**, *76*, 2878–2881.

(32) Dion, H. W.; Fusari, S. A.; Jahubowski, Z. L.; Zora, J. G.; Bartz, Q. R. *J. Am. Chem. Soc.* **1956**, *78*, 3075–3077.

(33) Imae, K.; Nihei, Y.; Oka, M.; Yamasaki, T.; Konishi, M.; Oki, T. *J. Antibiot.* **1993**, *46*, 1031–1033.